A randomized trial of 100 patients will evaluate whether selective low-dose alteplase transcatheter thrombolysis improves right-to-left ventricular ratio compared to standard anticoagulation in PE.
RCT (n=100)
Open-label
1:1
No
Does selective low-dose alteplase transcatheter thrombolysis improve the right ventricle to left ventricle ratio in patients with intermediate-high risk pulmonary embolism compared to standard anticoagulant therapy?
This study protocol outlines a randomized trial to evaluate the efficacy and safety of low-dose transcatheter thrombolysis compared to standard anticoagulation in intermediate-high risk pulmonary embolism.
Aim. Comparison of conservative and invasive treatment strategies in patients with intermediate-high risk pulmonary embolism (PE) based on a multimodal assessment of efficacy and safety. Material and methods. This single-center, open-label, randomized, comparative trial will include 100 patients with a verified diagnosis of PE with intermediate-high risk of 30-day mortality. Patients will be randomized 1:1 to standard anticoagulant therapy or selective low-dose alteplase transcatheter thrombolysis. Patients will be followed for 12 months. The primary endpoint is a decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. There are secondary endpoints: patient hemodynamic instability; ISTH major bleeding; Qanadli index decrease at 48 hours; degree of residual thrombosis with reduced perfusion at 3-6 months; incidence of post-thromboembolic syndrome at 3-6 months; 30-day, 90-day, and 1-year mortality. Conclusion. The study will provide important clinical data on the short- and long-term efficacy and safety of different treatment approaches in patients with intermediate-to-high-risk acute pulmonary embolism.
Simakova et al. (Tue,) conducted a rct in Intermediate-high risk pulmonary embolism (n=100). Selective low-dose alteplase transcatheter thrombolysis vs. Standard anticoagulant therapy was evaluated on Decrease in the right ventricle to left ventricle ratio by 20% or more from baseline at 48±6 hours after initiation of therapy. A randomized trial of 100 patients will evaluate whether selective low-dose alteplase transcatheter thrombolysis improves right-to-left ventricular ratio compared to standard anticoagulation in PE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: